Rigel Pharmaceuticals, Inc. (RIGL) Posts Q2 Loss of 26c/Share

Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) reported Q2 EPS of ($0.26), $0.04 better than the analyst estimate of ($0.30). Revenue for the quarter came in at $1.4 million versus the consensus estimate of $530 thousand.

For earnings history and earnings-related data on Rigel Pharmaceuticals, Inc. (RIGL) click here.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• C.H. Robinson acquires DeSpir Logistics for $75 million
• Goldman reinstates Estee Lauder rating, sees turnaround driving growth and margins